How have EVT shares performed in 2024?

Evotec's stock was trading at €21.28 at the beginning of 2024. Since then, EVT shares have decreased by 37.9% and is now trading at €13.21. View the best growth stocks for 2024 here .

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A) , AbbVie (ABBV) , ACADIA Pharmaceuticals (ACAD) , Anthem (ANTM) , AxoGen (AXGN) , Bank of America (BAC) , Booz Allen Hamilton (BAH) , Biohaven (BHVN) , Biogen (BIIB) and Blueprint Medicines (BPMC) .

ETR:EVT

Evotec (EVT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free EVT Stock Alerts

€13.21

-0.02 (-0.15%)

(As of 04/17/2024 ET)

Compare

Today's Range: €13.01
▼
€13.36
50-Day Range: €12.62
▼
€14.52
52-Week Range: €12.61
▼
€24.44

Volume: 617,970 shs
Average Volume: 1.36 million shs
Market Capitalization: $2.34 billion

P/E Ratio: N/A
Dividend Yield: 2.63%
Price Target: N/A

Stock Analysis Chart Headlines

Get Evotec alerts:

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Evotec Stock (ETR:EVT)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVT Stock News Headlines

April 17, 2024 | finanznachrichten.de

Evotec beruft Aurélie Dalbiez in den Vorstand

April 17, 2024 | finanznachrichten.de

Evotec SE: Evotec welcomes Aurélie Dalbiez as Chief People Officer

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | markets.businessinsider.com

EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer

April 17, 2024 | finance.yahoo.com

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

April 13, 2024 | finanznachrichten.de

ANALYSE: Deutsche Bank hebt Evotec auf 'Buy' - Frust nach Chef-Abgang überwunden

March 29, 2024 | finanznachrichten.de

Biotech Report: Evotec klettern, Qiagen fest

March 15, 2024 | finanznachrichten.de

Evotec-Aktie: Das wird spannend

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 6, 2024 | markets.businessinsider.com

EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic

February 22, 2024 | finanznachrichten.de

Evotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?Evotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?

February 6, 2024 | finanznachrichten.de

Evotec: Aktie fällt und fällt - das ist jetzt wichtig

February 3, 2024 | finanznachrichten.de

Evotec-Aktie fällt unter wichtige Marke. Wie sollen Anleger jetzt reagieren?

January 22, 2024 | finance.yahoo.com

Evotec SE: Invitation to Conference Call

January 8, 2024 | markets.businessinsider.com

EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb

January 8, 2024 | finance.yahoo.com

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

January 3, 2024 | markets.businessinsider.com

EQS-Adhoc: Evotec announces CEO transition

January 3, 2024 | finanznachrichten.de

Evotec SE: Evotec Announces CEO Transition

January 3, 2024 | markets.businessinsider.com

EQS-News: Evotec announces CEO transition

January 3, 2024 | finance.yahoo.com

Evotec Announces CEO Transition

December 14, 2023 | finance.yahoo.com

Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases

December 6, 2023 | msn.com

Evotec partner Jingxin receives approval for EVT201 in China

December 6, 2023 | markets.businessinsider.com

EQS-News: Evotec-partner Jingxin receives approval for EVT201 in China

November 8, 2023 | markets.businessinsider.com

Evotec 9-month Adj. EBITDA, Revenues Rise; Confirms FY23, Mid-term Outlook

November 8, 2023 | finance.yahoo.com

Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update

November 7, 2023 | fxstreet.com

Flat start to Monday after global equities posted best week in a year

October 6, 2023 | finance.yahoo.com

Further weakness as Evotec (ETR:EVT) drops 6.5% this week, taking three-year losses to 23%

See More Headlines

Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ETR
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: ETR:EVT
CUSIP: N/A
CIK: N/A
Web: www.evotec.com
Phone: +49-40-560810
Fax: N/A
Employees: 5,086
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): (€0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 62.70
P/E Growth: 0.98
Net Income: $-94,980,000.00
Net Margins: -11.57%
Pretax Margin: N/A
Return on Equity: -8.02%
Return on Assets: 0.17%

Debt

Debt-to-Equity Ratio: 51.61
Current Ratio: 2.16
Quick Ratio: 2.97

Sales & Book Value

Annual Sales: $820.80 million
Price / Sales: 2.85
Cash Flow: €3.83 per share
Price / Cash Flow: 3.45
Book Value: €6.45 per share
Price / Book: 2.05

Miscellaneous

Outstanding Shares: 177,190,000
Free Float: N/A
Market Cap: $2.34 billion
Optionable: Not Optionable
Beta: 1.11

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Mario Polywka DPHIL (Age 61)
Ph.D., Interim CEO, Member of the Management Board & Member of the Supervisory Board
Dr. Werner Lanthaler M.B.A. (Age 56)
MPA, Ph.D., Member of Management Board
Comp: $1.32M
Dr. Cord Dohrmann Ph.D. (Age 60)
Chief Scientific Officer & Member of Management Board
Comp: $804k
Dr. Craig Johnstone Ph.D. (Age 54)
COO & Member of Management Board
Comp: $712k
Dr. Matthias Evers Ph.D. (Age 51)
Chief Business Officer & Member of Management Board
Comp: $636k
Ms. Laetitia Rouxel (Age 50)
CFO & Member of Management Board
Ms. Anja Bosler
Principal Accounting Officer and Senior Vice President of Group Accounting
Mr. Volker Braun
Senior VP and Global Head of Investor Relations & ESG
Dr. Christian Dargel
EVP Global Head of Legal & Compliance
Gabriele Hansen
Senior VP & Head of Global Corporate Communications & Marketing

Key Competitors

View All Competitors

EVT Stock Analysis - Frequently Asked Questions

How have EVT shares performed in 2024?: Evotec's stock was trading at €21.28 at the beginning of 2024. Since then, EVT shares have decreased by 37.9% and is now trading at €13.21.
View the best growth stocks for 2024 here.
What other stocks do shareholders of Evotec own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

This page (ETR:EVT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial